Profil bibliographique

Nancy Chan

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

115Publications signalées

2160Citations signalées

3Affiliations récentes

Institutions déclarées

Western University London Health Sciences Centre NYU Langone Health

Domaines associés

Fibroblast Growth Factor ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchMedical Imaging and Pathology Studies

Publications récentes

Accès ouvert 2026 articleOpenAlex

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, G. Borges et autres

0 citationsClinical Cancer Research

Accès ouvert 2026 articleOpenAlex

From training to practice: a quality assurance evaluation of graduates’ experiences in a Canadian pathologists’ assistant program

Rilla J. Wei, Nancy Chan, Jina J. Y. Kum

0 citationsBMC Medical Education

Accès ouvert 2025 articleOpenAlex

Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021

Alexandra Thomas, Anthony Rhoads, Erica L. Mayer, Séamus O’Reilly et autres

2 citationsnpj Breast Cancer

Accès ouvert 2025 articleOpenAlex

A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

Shelley Potter, Kerry Avery, Rosina Ahmed, Jana de Boniface et autres

2 citationsnpj Breast Cancer

2025 conference-abstractOpenAlex

Abstract P2-08-09: Predictors of inadequate ovarian function suppression (OFS) in premenopausal women with hormone receptor (HR)-positive breast cancer receiving a gonadotropin-releasing hormone (GnRH) agonist in combination with endocrine therapy

Maryann Kwa, Leyla Bayat, Nancy Chan, Arturo Orlacchio et autres

0 citationsClinical Cancer Research

2025 conference-abstractOpenAlex

Abstract PS7-07: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC)

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Erika Hamilton et autres

1 citationClinical Cancer Research

2025 conference-abstractOpenAlex

Abstract PS7-06: Elacestrant combinations in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase 1b/2, open-label, umbrella study

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Erika Hamilton et autres

0 citationsClinical Cancer Research

2025 conference-abstractOpenAlex

Abstract P2-06-21: Preliminary validation of a multi-modal AI for stratification of early-stage breast cancer patients utilizing a foundation model for digital pathology

Jan Witowski, Joseph Cappadona, Jailan A. Elayoubi, Nancy Chan et autres

1 citationClinical Cancer Research

2025 conference-abstractOpenAlex

Abstract P2-07-21: A phase II study of pembrolizumab plus fulvestrant in ER positive, HER2 negative advanced/metastatic breast cancer patients

Nancy Chan, Dirk F. Moore, Nadia Baka, Kari B. Wisinski et autres

1 citationClinical Cancer Research

2025 conference-abstractOpenAlex

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.

Nancy Chan, Virginia Kaklamani, Sara M. Tolaney, Erika Hamilton et autres

3 citationsJournal of Clinical Oncology

Accès ouvert 2025 conference-abstractOpenAlex

Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Erika Hamilton et autres

2 citationsJournal of Clinical Oncology

2025 articleOpenAlex

Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.

Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Antonio Giordano et autres

1 citationJournal of Clinical Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.